ArticleJournal of Crohn's & colitis2021
Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.
Article in Journal of Crohn's & colitis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 74 citations in OpenAlex.
- Serum Immune Profiling in Paediatric Crohn's Disease Demonstrates Stronger Immune Modulation With First-Line Infliximab Than Conventional Therapy and Pre-Treatment Profiles Predict Clinical Response to Both Treatments.Journal of Crohn's & colitis · 2023Trial
- Uninflamed colonic tissue harbors humoral activity linked to anti-TNF therapy non-response in ulcerative colitis.iScience · 2026Article
- Proteomics in Gastrointestinal Diseases of Companion Animals: Current State and Knowledge Gaps.Animals : an open access journal from MDPI · 2026Review
- A novel diagnostic serum protein signature for pediatric inflammatory bowel disease.Journal of pediatric gastroenterology and nutrition · 2026Observational
- Plasma proteomic markers predict risk for bowel resection in inflammatory bowel disease: a retrospective cohort study.International journal of surgery (London, England) · 2026Article
- Serum immune profiling suggests overlap between IBD patients with joint complaints and patients with spondyloarthritis.Frontiers in immunology · 2026Article
- Plasma proteomic profiles identify biomarkers predicting Crohn's disease up to 16 years before onset.Nature communications · 2025Article
- Environmental and Inflammatory Factors Drive Perinuclear-Antineutrophil Cytoplasmic Antibodies (pANCA) in Ulcerative Colitis: A European Twin Study.United European gastroenterology journal · 2025Article
- Interpretable machine learning applied to high-dimensional salivary proteomics accurately classifies pediatric inflammatory bowel diseases.medRxiv : the preprint server for health sciences · 2025Article
- Serum proteins and faecal microbiota as potential biomarkers in newly diagnosed, treatment-naïve inflammatory bowel disease and irritable bowel syndrome patients.Journal of molecular medicine (Berlin, Germany) · 2025Article
- Properdin, transcortin and HGFAC are novel plasma biomarkers in canine chronic inflammatory enteropathies from active disease to remission.Scientific reports · 2025Article
- Integrating Proteomics into Personalized Medicine for Inflammatory Bowel Disease-Reality or Challenge?International journal of molecular sciences · 2025Review
- Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study.Journal of Crohn's & colitis · 2025Article
- Anti-integrin αvβ6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype.Journal of Crohn's & colitis · 2025Article
- Cohort profile: the Swedish Inception Cohort in inflammatory bowel disease (SIC-IBD).BMJ open · 2025Article
- Associations of 2923 plasma proteins with incident inflammatory bowel disease in a prospective cohort study and genetic analysis.Nature communications · 2025Article
- Genetic factors that predict response and failure of biologic therapy in inflammatory bowel disease.World journal of experimental medicine · 2025Review
- Inflammation-related Proteins Support Diagnosis of Inflammatory Bowel Disease and Are Modified by Exclusive Enteral Nutrition in Children With Crohn's Disease, Especially of Ileal Phenotype.Inflammatory bowel diseases · 2025Article
- An AI-assisted morphoproteomic approach is a supportive tool in esophagitis-related precision medicine.EMBO molecular medicine · 2025Article
- Unveiling the IL-1β/CXCL2 axis: a shared therapeutic target in periodontitis and inflammatory bowel disease.Frontiers in immunology · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
22 authors at 12 institutions in 6 countries.
Funding
Abstract
backgroundSuccess in personalized medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay [PEA] to identify diagnostic and prognostic biomarkers in inflammatory bowel disease [IBD].
methodsWe conducted a prospective case-control study in an inception cohort of 552 patients [328 IBD, 224 non-IBD], profiling proteins recruited across six centres. Treatment escalation was characterized by the need for biological agents or surgery after initial disease remission. Nested leave-one-out cross-validation was used to examine the performance of diagnostic and prognostic proteins.
resultsA total of 66 serum proteins differentiated IBD from symptomatic non-IBD controls, including matrix metallopeptidase-12 [MMP-12; Holm-adjusted p = 4.1 × 10-23] and oncostatin-M [OSM; p = 3.7 × 10-16]. Nine of these proteins are associated with cis-germline variation [59 independent single nucleotide polymorphisms]. Fifteen proteins, all members of tumour necrosis factor-independent pathways including interleukin-1 (IL-1) and OSM, predicted escalation, over a median follow-up of 518 [interquartile range 224-756] days. Nested cross-validation of the entire data set allowed characterization of five-protein models [96% comprising five core proteins ITGAV, EpCAM, IL18, SLAMF7 and IL8], which define a high-risk subgroup in IBD [hazard ratio 3.90, confidence interval: 2.43-6.26], or allowed distinct two- and three-protein models for ulcerative colitis and Crohn's disease respectively.
conclusionWe have characterized a simple oligo-protein panel that has the potential to identify IBD from symptomatic controls and to predict future disease course. Further prospective work is required to validate our findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.